



STRONG GROWTH IN 2009 REVENUES: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

<i>In millions of euros</i>	2009	2008	<i>Change</i>
Nominal revenues	252.2	234.4	+7.6%
Revenues at constant exchange rates	258.4	234.4	+10.2%
Revenues at constant exchange rates and scope	235.9	234.4	+0.6%

Strong growth in revenues

Vétoquinol's revenues in 2009 totalled 252.2 €M, an increase of 7.6% over the previous year. With exchange rates held constant, revenues increased by 10.2%. Thus exchange rates continued to have a negative effect, reducing sales growth by 2.6 percentage points, due to the decline in the pound sterling and the Polish zloty.

Revenues in Western Europe and North America benefited from the increase in the strength of sales teams, dynamic marketing campaigns, and management reorganisations in the Group in 2008.

Sales in Poland are once again on the path to growth, due mainly to management changes and the end of the pork crisis.

Revenues in the Asia Pacific region increased substantially following Vétoquinol's acquisition of the Animal Health Division of Wockhardt Limited in India at the end of August 2009.

Revenues increased significantly in each of Vétoquinol's three strategic therapeutic classes: anti-infectives, pain-inflammation and cardiology-nephrology.

Two-sided growth strategy

Vétoquinol achieved significant organic growth in the third and fourth quarters of 2009, the result of an expansion in sales teams and marketing campaigns conducted at the end of 2008 and throughout 2009.

Growth at the Group level is also based on a strategy of continued external growth, as evidenced by the acquisitions carried out in Italy at the end of 2008 and in India in August 2009. The Indian acquisition, which took place in a highly competitive context, demonstrates Vétoquinol's expertise in identifying acquisition targets and integrating its acquisitions into the Group.

The planned acquisition of a small Chinese laboratory has run into difficulties relating to local regulations. This in no way diminishes Vétoquinol's strategic interest in entering the Chinese market, which has great potential in the medium term.

Favourable outlook

The strong level of sales in the second half should enable the Group to record operating profit for the entire year that is in line with the levels reported at the end of the first half.

While sales forecasts should be read with caution, given that the animal health market is still recovering from the recent crisis, the resilience in Vétoquinol's sales should continue in 2010.

About Vétoquinol

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group specialized exclusively in animal health is the 11th largest laboratory in the world, and more than 80% of Vétoquinol's revenues come from outside France.

Vétoquinol engages in the research and development, production and marketing of medical and nutraceutical products. Vétoquinol has positioned itself in the curative sector, and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation, and cardiology/ nephrology.

The Group currently distributes its products in one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 different countries and a network of 140 distributor partners. The Company has more than 1,550 employees worldwide.

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Finance department

Pierre KONAREFF

Tel: +33 3 84 62 59 88

relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor relations

Emmanuel DOVERGNE

Tel: +33 1 56 43 44 63

emmanuel.dovergne@keima.fr

Media relations

Sibylle DESCAMPS DUBOIS

Tel: +33 1 56 43 44 72

sibylle.descamps@keima.fr

ANNEX

Revenues, in thousands of euros	2009	2008	<i>Change</i>	<i>Change with exchange rates held constant</i>	<i>Change with exchange rates and scope of business held constant</i>
1 st quarter	57,110	54,747	+4.3%	+7.7%	-1.8%
2 nd quarter	62,771	61,936	+1.3%	+3.4%	-4.6%
3 rd quarter	62,168	54,494	+14.1%	+17.4%	+4.9%
4 th quarter	70,165	63,218	+11.0%	+13.0%	+4.1%
Total for the year	252,214	234,395	+7.6%	+10.2%	+0.6%